The American Society for Gastrointestinal Endoscopy (ASGE) has recognized 32 endoscopy units as part of its program specifically dedicated to promoting quality in endoscopy, in all settings where it is practiced in the United States. The ASGE Endoscopy Unit Recognition Program honors endoscopy units that follow the ASGE guidelines on privileging, quality assurance, endoscopy reprocessing and CDC infection control guidelines. To date, 166 endoscopy units have been recognized by ASGE. "ASGE is delighted to be recognizing these 32 endoscopy units, whose staff work hard every day to provide high-quality care to their patients in a safe environment, " said Bret T.
Non-Hospitalised Patients With Active Inflammatory Bowel Disease Are 16 Times More Likely To Suffer A Blood Clot Than The General Population
Non-hospitalised patients with active inflammatory bowel disease (IBD) are 16 times more likely to suffer a blood clot (venous thromboembolism) than the non-hospitalised general population. These results suggest that active IBD in ambulatory patients might be a far greater risk factor for venous thromboembolism than previously recognised, and these patients could be a target for prophylaxis. These are the conclusions of an Article published Online First (http://www.thelancet.com) and in an upcoming edition of The Lancet -written by Dr Matthew J Grainge, University of Nottingham, UK, and colleagues. Venous thromboembolism in the leg is associated with a short-term mortality rate of about 6%, whereas the rate after embolism in the pulmonary circulation is as high as 20%.
Gastric cancer remains a significant problem globally. The relationship between intestinal metaplasia (IM) and gastric cancer has always been controversial. Generally IM is divided into subtypes on the basis of histochemical characteristics; however, this classification is confusing. A new classification of IM is needed in order to follow up patients selectively. A research team led by Prof Zhang of the Department of Pathology, Qilu Hospital of Shandong University first proposed the classification of IM into SIM and AIM. The research project has won a Scientific Progress Award from the Board of Education, Shandong Province, China. A research article published in the World Journal of Gastroenterology lies in the novel classification of IM where IM is divided into simple IM (SIM) and atypical IM (AIM).
Gastric cancer, one of the most common types of cancer, is associated with high mortality rates. In the last decades, a decrease in the worldwide incidence has been observed with some changes in the therapeutic and diagnostic options. However, the prognosis for this disease still remains poor, mainly when the diagnosis is performed at advanced stages. The therapy most effective is still surgical resection and in a significant number of cases, especially in the advanced stage, it is only palliative. Thus, it is of extreme importance to study the mechanisms that act in gastric carcinogenesis and research possible markers that can assist in earlier diagnosis.
Although several studies pertaining to the natural history of subepithelial tumors have been published, they have been limited by small sample size and relatively short follow-up. The natural history of subepithelial lesions has not been clearly elucidated, and the appropriate management strategy for small subepithelial tumors is still controversial. A research article published on January 28, 2010 in the World Journal of Gastroenterology addresses this problem. The research team from South Korea reviewed the medical records of 104 159 patients who underwent upper gastrointestinal endoscopy at the Center for Health Promotion of Samsung Medical Center between 1996 and 2003.
An investigational drug that inhibits serotonin synthesis in the gut, administered orally once daily, effectively cured osteoporosis in mice and rats reports an international team led by researchers from Columbia University Medical Center, in the Feb. 7 issue of Nature Medicine. Serotonin in the gut has been shown in recent research to stall bone formation. The finding could lead to new therapies that build new bone; most current drugs for osteoporosis can only prevent the breakdown of old bone. "New therapies that inhibit the production of serotonin in the gut have the potential to become a novel class of drugs to be added to the therapeutic arsenal against osteoporosis, " said Gerard Karsenty, M.